An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

BACKGROUND: We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma. METHODS: We used generalized pairwise comparisons. This statistical method permits the simultaneous analysis of several prioritized outcome measures. The f...

Descripción completa

Detalles Bibliográficos
Autores principales: Péron, Julien, Roy, Pascal, Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Gourgou-Bourgade, Sophie, Stanbury, Trevor, Roche, Laurent, Ozenne, Brice, Buyse, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347744/
https://www.ncbi.nlm.nih.gov/pubmed/27765912
http://dx.doi.org/10.18632/oncotarget.12761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347744/
https://www.ncbi.nlm.nih.gov/pubmed/27765912
http://dx.doi.org/10.18632/oncotarget.12761

Ejemplares similares